148 related articles for article (PubMed ID: 12631628)
1. Oncolytic viral therapy for human pancreatic cancer cells by reovirus.
Etoh T; Himeno Y; Matsumoto T; Aramaki M; Kawano K; Nishizono A; Kitano S
Clin Cancer Res; 2003 Mar; 9(3):1218-23. PubMed ID: 12631628
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models.
Himeno Y; Etoh T; Matsumoto T; Ohta M; Nishizono A; Kitano S
Int J Oncol; 2005 Oct; 27(4):901-6. PubMed ID: 16142304
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oncolytic reovirus against human breast cancer cells.
Hata Y; Etoh T; Inomata M; Shiraishi N; Nishizono A; Kitano S
Oncol Rep; 2008 Jun; 19(6):1395-8. PubMed ID: 18497942
[TBL] [Abstract][Full Text] [Related]
4. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
5. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
Yang WQ; Senger D; Muzik H; Shi ZQ; Johnson D; Brasher PM; Rewcastle NB; Hamilton M; Rutka J; Wolff J; Wetmore C; Curran T; Lee PW; Forsyth PA
Cancer Res; 2003 Jun; 63(12):3162-72. PubMed ID: 12810644
[TBL] [Abstract][Full Text] [Related]
6. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
8. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
Miura Y; Ohnami S; Yoshida K; Ohashi M; Nakano M; Ohnami S; Fukuhara M; Yanagi K; Matsushita A; Uchida E; Asaka M; Yoshida T; Aoki K
Cancer Lett; 2005 Jan; 218(1):53-62. PubMed ID: 15639340
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
Hatanaka K; Suzuki K; Miura Y; Yoshida K; Ohnami S; Kitade Y; Yoshida T; Aoki K
J Gene Med; 2004 Oct; 6(10):1139-48. PubMed ID: 15452878
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
12. Molecular target-based therapy of pancreatic cancer.
Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
[TBL] [Abstract][Full Text] [Related]
13. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice.
Hase R; Miyamoto M; Uehara H; Kadoya M; Ebihara Y; Murakami Y; Takahashi R; Mega S; Li L; Shichinohe T; Kawarada Y; Kondo S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8737-44. PubMed ID: 16361561
[TBL] [Abstract][Full Text] [Related]
14. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
Jin K; Park S; Ewton DZ; Friedman E
Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
[TBL] [Abstract][Full Text] [Related]
15. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
Shmulevitz M; Marcato P; Lee PW
Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
[TBL] [Abstract][Full Text] [Related]
17. Reovirus oncolysis in human head and neck squamous carcinoma cells.
Ikeda Y; Nishimura G; Yanoma S; Kubota A; Furukawa M; Tsukuda M
Auris Nasus Larynx; 2004 Dec; 31(4):407-12. PubMed ID: 15571915
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression promotes reovirus therapy of colorectal liver metastases.
Smakman N; van der Bilt JD; van den Wollenberg DJ; Hoeben RC; Borel Rinkes IH; Kranenburg O
Cancer Gene Ther; 2006 Aug; 13(8):815-8. PubMed ID: 16543920
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.
Fu X; Tao L; Li M; Fisher WE; Zhang X
Clin Cancer Res; 2006 May; 12(10):3152-7. PubMed ID: 16707615
[TBL] [Abstract][Full Text] [Related]
20. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
Yanagie H; Tanabe T; Sumimoto H; Sugiyama H; Matsuda S; Nonaka Y; Ogiwara N; Sasaki K; Tani K; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 May; 63(4):275-86. PubMed ID: 18657378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
